253 related articles for article (PubMed ID: 22334023)
1. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
Iankov ID; Allen C; Federspiel MJ; Myers RM; Peng KW; Ingle JN; Russell SJ; Galanis E
Mol Ther; 2012 Jun; 20(6):1139-47. PubMed ID: 22334023
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.
Iankov ID; Haralambieva IH; Galanis E
Vaccine; 2011 Feb; 29(8):1710-20. PubMed ID: 21182995
[TBL] [Abstract][Full Text] [Related]
3. An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.
Ramachandran M; Yu D; Wanders A; Essand M; Eriksson F
Mol Ther; 2013 Nov; 21(11):2008-18. PubMed ID: 23817216
[TBL] [Abstract][Full Text] [Related]
4. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.
Iankov ID; Msaouel P; Allen C; Federspiel MJ; Bulur PA; Dietz AB; Gastineau D; Ikeda Y; Ingle JN; Russell SJ; Galanis E
Breast Cancer Res Treat; 2010 Aug; 122(3):745-54. PubMed ID: 19894113
[TBL] [Abstract][Full Text] [Related]
5. Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.
Iankov ID; Federspiel MJ; Galanis E
Vaccine; 2013 Oct; 31(42):4795-801. PubMed ID: 23948230
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
7. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.
Iankov ID; Kurokawa CB; D'Assoro AB; Ingle JN; Domingo-Musibay E; Allen C; Crosby CM; Nair AA; Liu MC; Aderca I; Federspiel MJ; Galanis E
Cancer Gene Ther; 2015 Sep; 22(9):438-44. PubMed ID: 26272026
[TBL] [Abstract][Full Text] [Related]
9. Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an
Viker KB; Steele MB; Iankov ID; Concilio SC; Ammayappan A; Bolon B; Jenks NJ; Goetz MP; Panagioti E; Federspiel MJ; Liu MC; Peng KW; Galanis E
Mol Ther Methods Clin Dev; 2022 Sep; 26():532-546. PubMed ID: 36092362
[TBL] [Abstract][Full Text] [Related]
10. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
11. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
12. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
[TBL] [Abstract][Full Text] [Related]
13. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
[TBL] [Abstract][Full Text] [Related]
14. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
[TBL] [Abstract][Full Text] [Related]
15. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
Allen C; Opyrchal M; Aderca I; Schroeder MA; Sarkaria JN; Domingo E; Federspiel MJ; Galanis E
Gene Ther; 2013 Apr; 20(4):444-9. PubMed ID: 22914495
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
18. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
19. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]